Asthma in the context of global alliance against respiratory diseases (GARD) in Turkey

Yorgancıoğlu, Arzu; Gemicioğlu, Bilun; Ekinci, Banu; Özkan, Zübeyde; Bayram, Hasan; Ergan, Begüm; Ersu, Refika; Kocabaş, Ali; Köktürk, Nurdan

doi:10.21037/jtd.2018.03.39

Cited by 14 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This seems to be the first AHA national project Portugal National coordination and national plan for all chronic respiratory diseases [ 45 ] The national coordination is led by the Directorate General of Health and includes all stakeholders required for a national plan which is deployed in the regions. The plan follows the Portuguese National Programme for Respiratory Diseases (PNDR) Turkey National coordination and Role of the chronic respiratory disease action plan on the ministerial Noncommunicable Diseases action plan [ 46 , 47 ] The first national coordination of GARD including the Ministry of Health, WHO national office and major societies. Extremely successful programme with all public and private stakeholders of a country.…”

Section: Application Of the Eip On Aha Scaling Up Strategy To Chronicmentioning

confidence: 99%

See 1 more Smart Citation

Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

Bousquet

Farrell

Crooks³

et al. 2016

Clin Transl Allergy

View full text Add to dashboard Cite

Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) focuses on the integrated care of chronic diseases. Area 5 (Care Pathways) was initiated using chronic respiratory diseases as a model. The chronic respiratory disease action plan includes (1) AIRWAYS integrated care pathways (ICPs), (2) the joint initiative between the Reference site MACVIA-LR (Contre les MAladies Chroniques pour un VIeillissement Actif) and ARIA (Allergic Rhinitis and its Impact on Asthma), (3) Commitments for Action to the European Innovation Partnership on Active and Healthy Ageing and the AIRWAYS ICPs network. It is deployed in collaboration with the World Health Organization Global Alliance against Chronic Respiratory Diseases (GARD). The European Innovation Partnership on Active and Healthy Ageing has proposed a 5-step framework for developing an individual scaling up strategy: (1) what to scale up: (1-a) databases of good practices, (1-b) assessment of viability of the scaling up of good practices, (1-c) classification of good practices for local replication and (2) how to scale up: (2-a) facilitating partnerships for scaling up, (2-b) implementation of key success factors and lessons learnt, including emerging technologies for individualised and predictive medicine. This strategy has already been applied to the chronic respiratory disease action plan of the European Innovation Partnership on Active and Healthy Ageing. Electronic supplementary materialThe online version of this article (doi:10.1186/s13601-016-0116-9) contains supplementary material, which is available to authorized users.

show abstract

Section: Application Of the Eip On Aha Scaling Up Strategy To Chronicmentioning

confidence: 99%

“…Excellent example for scale up strategy AIRWAYS ICPs study groups exist in all but 2 European Union countries (Luxembourg, Malta). They follow the GARD model deployed in Turkey [ 46 , 47 ] and Italy [ 13 , 48 ]. Governments of countries (e.g.…”

Section: Application Of the Eip On Aha Scaling Up Strategy To Chronicmentioning

confidence: 99%

Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

Bousquet

Farrell

Crooks³

et al. 2016

Clin Transl Allergy

View full text Add to dashboard Cite

show abstract

“…A patient‐centered mobile application (allergy diary), which uses visual analog scale scores and enables a daily assessment of rhinitis and asthma control by patients themselves, has been developed for iOS and Android smartphones. Moreover, a pediatric coordination group has been established to formulate pediatric action plans (Yorgancıoglu et al, ). Accordingly, an interdisciplinary collaboration between nursing respiratory teams is essential to prevent respiratory infections and their comorbidities.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of upper respiratory tract infections and associated factors among children in Turkey

Çınaroğlu

2019

Specialist Pediatric Nursing

View full text Add to dashboard Cite

Purpose: Upper respiratory tract infections (URIs) are the most common diseases observed in children aged 0-6 years in Turkey. This study was conducted to investigate URIs in 0-6 year-old children in Turkey. Design and Methods: Data of children aged 0-6 years who were included in the 2014 Turkey Health Survey conducted by the Turkish Statistical Institute were collected from their parents.Results: In total, 1,293 and 1,732 children with and without URIs, respectively, were identified. The weighted point prevalence of URIs was 42.23%. Compared with the uninsured and female children belonging to high-income families, insured male children belonging to low-income families were more likely to develop URIs (p < .001). Moreover, comorbidities such as communicable diseases, anemia and diarrhea, and factors like health services utilization were associated with URIs.Analysis of health services utilization highlights that URIs were reported more among the children who had not visited a hospital than among those who had visited a hospital, with an odds ratio of 1.23. Conclusions:The results of this study provide a deeper understanding of sociodemographic, comorbid, and health services utilization factors associated with URIs.These results provide useful insights for pediatric nursing professionals to improve the quality and efficiency of pediatric respiratory nursing services.Practice Implications: Collaborative networks with other health professionals, parents, and public health policy-makers are essential to decrease the prevalence of URIs in Turkey. These study results provide several insights for health professionals to improve pediatric action plans for ultimately improving child health status. K E Y W O R D S children, prevalence, respiratory care, Turkey, upper respiratory tract infections 1 | WHAT IS CURRENTLY KNOWN? Upper respiratory tract infections (URIs) are the most common diseases among children aged 0-6 years in Turkey. However, there is a lack of knowledge about the factors associated with URIs among children. | WHAT DOES THIS ARTICLE ADD?This study adds value by highlighting the prevalence of URIs that was 42.23% among 0-6 year-old children in Turkey during the year 2014.Moreover, male and insured children belonging to low-income families are more likely to experience URIs and communicable diseases (varicella and mumps), diarrhea, and anemia are the comorbidities strongly associated with URIs.

show abstract

“…Two scenarios were analysed and compared in terms of costs of inhalers and environmental impact; one scenario (without RESPIMAT re-usable) in which the three brands were used together with a Respimat disposable inhaler and another scenario (with RESPIMAT re-usable) in which RESPIMAT disposable was replaced by a RESPIMAT re-usable inhaler. Given that RESPIMAT re-usable were launched in April (1) kg CO 2 e = Activity Data (unit) × emission factor kg GHG unit × GWP CO 2 e kg GHG .…”

Section: Scenario Analysismentioning

confidence: 99%

“…The World Health Organization (WHO) estimates that chronic respiratory diseases represent 5% of total disease burden and 8.3% of chronic disease burden worldwide and account for more than 4 million deaths each year [1], 150,000 of which occur in the European Union [2]. About 210 million people are estimated to have chronic obstructive pulmonary disease (COPD) worldwide [3] and an estimated 300 million people suffer from asthma [4,5].…”

Section: Introductionmentioning

confidence: 99%

Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT® Re-usable Inhaler

Ortsäter

Borgström

Baldwin

et al. 2019

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Background RESPIMAT ® re-usable enables patients to re-use the inhaler and its availability therefore reduces the number of inhalers and associated wastage. Objective The objective of this study was to perform an economic evaluation that incorporates the ecological impact of adopting RESPIMAT re-usable into the healthcare system in Germany. Methods Inhaler costs and environmental impact over 5 years in Germany in a scenario with RESPIMAT re-usable compared to a scenario without RESPIMAT re-usable were estimated using a budget impact model. The carbon emissions were derived for each treatment pattern considering the whole life cycle (cradle-to-grave) of the inhaler product. The cost of carbon emissions was estimated using a societal cost per ton of carbon emission. Results By introducing RESPIMAT re-usable in Germany, it was estimated that by 2023, the number of inhalers used would have decreased by 5,748,750 compared to a scenario without RESPIMAT re-usable. In addition, this measure would reduce the environmental burden of inhaler use while at the same time reducing medical cost of inhalers. Conclusions Adopting RESPIMAT ® re-usable to the national healthcare services may be a cost-saving option, which has the additional benefit of reducing the societal cost of carbon emissions. JEL Classification Q51 • Q58 Key Points for Decision Makers The healthcare sector is a major contributor to emissions of global greenhouse gases A broader approach to include the environmental effect when evaluating new health technologies may better capture the true value of a new product RESPIMAT re-usable reduces the societal cost of carbon emissions * Gustaf Ortsäter

show abstract

Asthma in the context of global alliance against respiratory diseases (GARD) in Turkey

Cited by 14 publications

References 21 publications

Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

Prevalence of upper respiratory tract infections and associated factors among children in Turkey

Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT® Re-usable Inhaler

Contact Info

Product

Resources

About